This trial is evaluating whether ELU001 will improve 2 primary outcomes and 3 secondary outcomes in patients with Ovary Cancer. Measurement will happen over the course of 28 days.
This trial requires 166 total participants across 1 different treatment group
This trial involves a single treatment. ELU001 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"Contrary to its dismal prognosis, CCA is a very rare cancer. The incidence of CCA seems to be increasing in recent years, but the cause of this increase is unknown. Patients with extrahepatic bile duct cancers should undergo surgical resection as soon as possible so that they can be cured of this deadly disease. In patients who do not respond to surgical resection, intraoperative frozen section analysis may help predict tumor recurrence." - Anonymous Online Contributor
"Cholangiocarcinoma incidence rates are increasing in the United States. This increase is driven largely by an increase in high-risk patients (women, persons older than 65 years, black persons) and increased resection rates for CCA." - Anonymous Online Contributor
"Cholangiocarcinoma is not rare, and its prognosis is poor. Nevertheless, there were no differences between patients who had cholangiocarcinoma and those who did not. The survival rate after curative resection was similar in both groups. Thus, curative resection should be performed when possible regardless of whether the cancer is benign or malignant." - Anonymous Online Contributor
"The majority of bile duct malignancies were associated with chronic liver diseases (especially HCV infection and alcoholic liver disease), but not with traditional risk factors. Bile duct cancer may have multiple etiologies and is likely underdiagnosed because of its nonspecific clinical presentation." - Anonymous Online Contributor
"Survival was significantly better for patients with CCA than for those with adenocarcinoma when all variables and tumor characteristics were taken into account. The best survival was for patients with CCA resected surgically (surgery alone or combined with adjuvant chemoradiotherapy) while patients with CCA derived from the perihilar region had an even better prognosis. Survival was worse for patients with CCA arising from the liver, pancreas, gall bladder, or lymph node metastasis who could not have their primary tumor resected surgically. Patients who received neoadjuvant chemotherapy before surgery showed a better survival than those who received postoperative chemotherapy, whereas combination therapy did not show any benefit over monotherapy." - Anonymous Online Contributor
"The patient enrolled In a recent study received elu001 at a dose of 1 mg/kg every 3 weeks for 24 weeks. Serious adverse events were observed in patients treated with elu001. All patients were hospitalized and a significant number of patients required elimination from the study. Physicians need to be aware of these serious side effects when using elu001." - Anonymous Online Contributor
"The incidence of severe reactions was similar to that reported previously. In contrast, there was no evidence of increased risk of hepatic toxicity or neurological toxicity compared with historical controls. Elucidation of the mechanism(s) responsible for the adverse reactions observed has not been established. However, available data do not support a major role for elu001 as a causative agent for these reactions." - Anonymous Online Contributor
"The combination of elu001 and a standard chemotherapy regimen may offer better results in advanced CCA. Elu001 may be useful in the therapy of some patients with unresectable CCA. Further studies should assess the efficacy of elu001 as a monotherapy before it is used as part of a combination regimen." - Anonymous Online Contributor
"Findings from a recent study showed a strong association between multiple endocrine neoplasia type 1 alleles and CC in the Chinese population, supporting the role of hereditary factors in CC genesis." - Anonymous Online Contributor
"Elu001 is a new type of MRI contrast agent without any known side effects for hepatic imaging. Results from a recent paper suggest that elu001 may be useful in distinguishing benign from malignant liver lesions, especially for patients with equivocal or indeterminate liver masses on the basis of conventional MRI." - Anonymous Online Contributor
"The risk of developing cholangiocarcinoma increases with age, particularly after age 60. In addition to surgical resection, the use of endoscopic ultrasound (EUS) to staging the tumor may allow improved detection of early tumors and should be considered when investigating the presence of biliary strictures. The detection rate of intrahepatic cholangiocarcinoma was significantly higher in EUS-based compared to ERCP-based staging, and EUS showed better performance in detecting lymph node involvement and distant metastasis." - Anonymous Online Contributor